interstitial lung disease in systemic sclerosis. Systemic sclerosis [scleroderma], 6MWT, interstitial lung diseases, body plethysmography, DLCO, Tadalafil,
Conditions
Interventions
Intervention 1: Intervention group 1: Patients with sclerodermia and pulmonary hypertension: Individuals will receive 10 mg oral tadalafil (Adacirca) for the first two weeks and then 20 mg for 22weeks
Sponsors
Vice Chancellor of the National Research Institute of Tuberculosis and Lung Diseases
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: sclerodermic patients with parenchymal involvement and with pulmonary hypertension sclerodermic patients with parenchymal involvement and without pulmonary hypertension
Exclusion criteria
Exclusion criteria: others etiology of pulmonary hypertension use of other drugs of pulmonary hypertension use of nitrates and alpha receptor blockers Patient Satisfaction To Get Tadalafil
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 6 minutes walking test. Timepoint: before intervention, and 6 months after initiation of intervention. Method of measurement: puls oximeter divice. | — |
Secondary
| Measure | Time frame |
|---|---|
| Diffusion of lung carbon monoxide. Timepoint: before intervention and 6 months after initiation of intervention. Method of measurement: device of diffusion of lung carbon monoxide calculator.;Body plethysmography. Timepoint: before intervention, and 6 months after intervention. Method of measurement: device of body pletysmograpgy.;FEV1, FVC. FEV1/FVC. Timepoint: before the study and 6 months after initiation of study. Method of measurement: spirometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahboubeh Darban
Semnan University of Medical Sciences
Outcome results
None listed